Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study

Raajit K. Rampal, MD PhD, Srdan Verstovsek, MD PhD, Sean M. Devlin, PhD, Amber C. King, PharmD, BCOP, Eytan M. Stein, MD, Naveen Pemmaraju, MD, Michael J. Mauro, MD, Tapan M. Kadia, MD, Guillermo Montalban-Bravo, MD, Kelsey Alvarez, RN, Nicole Ard, Tawni Goodman, Bria Taylor, Prithviraj Bose, MD

Blood (2019) 134 (Supplement_1): 4163.

https://doi.org/10.1182/blood-2019-127661

Published: 2019

Journal Articles

Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Jorge E. Cortes, MD, Daniel J. DeAngelo, MD, Harry P. Erba, MDPhD, Elie Traer, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, Cecilia Arana-Yi, MD, William Blum, MD, Callum M. Sloss, PhD, Kerry Culm-Merdek, Patrick A. Zweidler-McKay, MD PhD, Eunice S. Wang, MD

Blood (2018) 132 (Supplement 1): 26.

https://doi.org/10.1182/blood-2018-99-112891

Published: 2018

Journal Articles

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study

Raajit K. Rampal, MD PhD, Srdan Verstovsek, MD PhD, Sean M Devlin, PhD, Eytan M. Stein, MD, Tapan M. Kadia, MD, Michael J. Mauro, MD, Naveen Pemmaraju, MD, Kelsey Alvarez, RN, Nicole Ard, Tawni Goodman, Kelly Marek, Prithviraj Bose, MD

Blood (2018) 132 (Supplement 1): 354.

https://doi.org/10.1182/blood-2018-99-114125

Published: 2018

Journal Articles

Von Willebrand Disease and Gastrointestinal Bleeding: A National Inpatient Sample (NIS) Study

Anastasia Tsagianni, MD, Margaret V. Ragni, MD MPH, Diane M. Comer, BS, Jonathan G. Yabes, PhD

Blood (2018) 132 (Supplement 1): 1179.

https://doi.org/10.1182/blood-2018-99-111731

Published: 2018

Journal Articles

Treatment-Related Infections and Risk Factors in Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib

Amber C King, PharmD, BCOP, Meier Hsu, MS, Michael J. Mauro, MD, Raajit K. Rampal, MD, PhD

Blood (2016) 128 (22): 1930.

https://doi.org/10.1182/blood.V128.22.1930.1930

Published: 2016

Journal Articles

Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Susan O'Brien, Nicole Lamanna, MD, Thomas J. Kipps, MD PhD, Ian W. Flinn, MD PhD, Andrew D. Zelenetz, MD PhD, Jan A. Burger, MD PhD, Leanne M. Holes, Yoonjin Cho, PhD, Ronald L. Dubowy, MD, Steven E. Coutre, MD

Blood (2014) 124 (21): 1994.

https://doi.org/10.1182/blood.V124.21.1994.1994

Published: 2014

Journal Articles

Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL)

Kami J. Maddocks, MD, John Pagel, MD PhD, John C. Byrd, MD, Scott Stromatt, Farrukh Awan, MD MS

Blood (2014) 124 (21): 4671.

https://doi.org/10.1182/blood.V124.21.4671.4671

Published: 2014

Journal Articles

Outcomes Of Colonoscopies In Patients With Bleeding Disorders

Ashley N Cobb, BA, Amy Eckerman, RN, Rajiv K Pruthi, MBBS

Blood (2013) 122 (21): 1115.

https://doi.org/10.1182/blood.V122.21.1115.1115

Published: 2013

Journal Articles

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Robert W. Chen, MD, Leslie Popplewell, MD, Paul Frankel, PhD, Tanya Siddiqi, MD, Joel Conrad, BS, Michelle Mott, RN, Myo Htut, MD, Auayporn Nademanee, MD, Stephen J Forman, MD, Mark Kirschbaum, MD

Blood (2012) 120 (21): 3698.

https://doi.org/10.1182/blood.V120.21.3698.3698

Published: 2012

Journal Articles

Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses – First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial

Blood (2012) 120 (21): 550.

https://doi.org/10.1182/blood.V120.21.550.550

Published: 2012

Journal Articles

The Role of PET-CT for the Diagnosis of Infections in Hemato-Oncological Patients with Persistent Febrile Neutropenia

Anat Gafter-Gvili, MD, Mical Paul, MD, Hanna Bernstine, MD, Liat Vidal, MD, Ron Ram, MD, Pia Raanani, MD, Moshe Yeshurun, MD, Boaz Tadmor, MD, Ofer Shpilberg, MD, MPH, David Groshar, MD

Blood (2011) 118 (21): 4289.

https://doi.org/10.1182/blood.V118.21.4289.4289

Published: 2011

Journal Articles

High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma

Anne W Beaven, MD, David A. Rizzieri, MD, Zachary Powell, Zhiguo Li, PhD, Peggy Alton, RN, Julie Warzecho, RN, Louis F. Diehl, MD, Joseph O. Moore, MD, Carlos Manuel de Castro, III, MD, Jon P. Gockerman, MD

Blood (2011) 118 (21): 2681.

https://doi.org/10.1182/blood.V118.21.2681.2681

Published: 2011

Journal Articles

The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography and CT (PET-CT) for the Diagnosis of Infections in Hemato-Oncological Patients with Persistent Neutropenia and Fever.

Anat Gafter-Gvili, MD, Hanna Bernstine, MD, Liat Vidal, MD, Mical Paul, MD, Ron Ram, MD, Pia Raanani, MD, Moshe Yeshurun, Ofer Shpilberg, MD, MPH, David Groshar, MD

Blood (2009) 114 (22): 3121.

https://doi.org/10.1182/blood.V114.22.3121.3121

Published: 2009

Journal Articles

Double Hematological Malignancy: An Unusual Presentation in Three Cases

Rami Y. Haddad, MD, FACP, Navneet Attri, MD, Yaser Kawar, MD

Blood (2008) 112 (11): 5294.

https://doi.org/10.1182/blood.V112.11.5294.5294

Published: 2008

Journal Articles

High-Dose Therapy with Peripheral Blood Stem Cell Transplantation for Patients with Relapsed or Refractory Hodgkin’s Disease: A Single-Institution 20-Year Follow-up Experience.

Kai Neben, MD, Julia Meissner, MD, Sascha Dietrich, MD, Manfred Hensel, MD, Alwin Krämer, MD, Mathias Witzens-Harig, MD, Peter Dreger, MD, Anthony D. Ho, MD

Blood (2008) 112 (11): 2145.

https://doi.org/10.1182/blood.V112.11.2145.2145

Published: 2008

Journal Articles

Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination with Bortezomib in Patients with Advanced Multiple Myeloma.

Donna M. Weber, Sundar Jagannath, Amitabha Mazumder, Ronald Sobecks, Gary J. Schiller, Maria Gavino, Chantelle Sumbler, Carrie McFadden, Cong Chen, Justin L. Ricker, Syed Rizvi, Carol Oerth, Patricia Brownell, Mohamad A. Hussein

Blood (2007) 110 (11): 1172.

https://doi.org/10.1182/blood.V110.11.1172.1172

Published: 2007

Journal Articles

Mucosal Foxp3 + Regulatory T Cells Show Significant Numerical Differences in Patients with Intestinal Graft-Versus-Host Disease Compared to Infectious Diseases of the Gut.

Kathrin Rieger, Christoph Loddenkemper, Jochen Maul, Thomas Fietz, Daniel Wolff, Harald Terpe, Beate Steiner, Erika Berg, Stefan Miehlke, Martin Bornhaeuser, Thomas Schneider, Martin Zeitz, Harald Stein, Eckhard Thiel, Lutz Uharek

Blood (2005) 106 (11): 596.

https://doi.org/10.1182/blood.V106.11.596.596

Published: 2005

Journal Articles

18 F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET): An Important Tool in the Management of Infection in Patients with Hematological Cancer.

Elias J. Anaissie, MD, Marisa H. Miceli, MD, Steve D. Strout, Laurie Jones-Jackson, MD, Ronald C. Walker, MD, Gary Purnell, MD, Jose A. Diaz, MD, Fariba Saghafifar, MD, Klaus A. Hollmig, MD, Anasthasios Fassas, MD, Guido Tricot, MD, Bart Barlogie, MD

Blood (2004) 104 (11): 1160.

https://doi.org/10.1182/blood.V104.11.1160.1160

Published: 2004

Journal Articles

Propofol-Induced Bleeding Dyscrasia: A Case Report.

Rabih C. Fahed, MD, Thomas K. Schulz2, MD

Blood (2004) 104 (11): 3894.

https://doi.org/10.1182/blood.V104.11.3894.3894

Published: 2004

Journal Articles

Combination Therapy with CC-5013 (Lenalidomide; Revlimid™) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).

S. Vincent Rajkumar, MD, Suzanne R. Hayman, MD, Martha Q. Lacy, MD, Angela Dispenzieri, MD, Antje Hoering, PhD, Susan M. Geyer, PhD, Steven R. Zeldenrust, MD, PhD, Philip R. Greipp, MD, Rafael Fonseca, MD, John A. Lust, MD, PhD, Stephen J. Russell, MD, PhD, Robert A. Kyle, MD, Thomas E. Witzig, MD, Morie A. Gertz, MD

Blood (2004) 104 (11): 331.

https://doi.org/10.1182/blood.V104.11.331.331

Published: 2004

NARROW

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study

Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study

Von Willebrand Disease and Gastrointestinal Bleeding: A National Inpatient Sample (NIS) Study

Treatment-Related Infections and Risk Factors in Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib

Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL)

Outcomes Of Colonoscopies In Patients With Bleeding Disorders

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses – First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial

The Role of PET-CT for the Diagnosis of Infections in Hemato-Oncological Patients with Persistent Febrile Neutropenia

High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma

The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography and CT (PET-CT) for the Diagnosis of Infections in Hemato-Oncological Patients with Persistent Neutropenia and Fever.

Double Hematological Malignancy: An Unusual Presentation in Three Cases

High-Dose Therapy with Peripheral Blood Stem Cell Transplantation for Patients with Relapsed or Refractory Hodgkin’s Disease: A Single-Institution 20-Year Follow-up Experience.

Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination with Bortezomib in Patients with Advanced Multiple Myeloma.

Mucosal Foxp3 + Regulatory T Cells Show Significant Numerical Differences in Patients with Intestinal Graft-Versus-Host Disease Compared to Infectious Diseases of the Gut.

18 F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET): An Important Tool in the Management of Infection in Patients with Hematological Cancer.

Propofol-Induced Bleeding Dyscrasia: A Case Report.

Combination Therapy with CC-5013 (Lenalidomide; Revlimid™) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only